NHS Urged to Accelerate Weight Loss Jab Usage Amid Drug Advancements

Experts are calling for the NHS to speed up the adoption of weight loss injections as society enters a promising era for these medications.

Obesity is linked to numerous long-term health issues, such as cancer, heart disease, dementia, and diabetes, puting significant pressure on NHS resources.

Studies indicate that weight loss drugs like Semaglutide, known commercially as Wegovy and Ozempic, are connected to a lower risk of 42 medical conditions, including certain cancers and heart problems.

It’s estimated that approximately 3.8 billion people, including nearly 750 million children and adolescents, will be classified as overweight or obese by 2050.

A recent study shared at the European Obesity Conference on Tuesday, supported by Novo Nordisk, suggests that Wegovy can halve the risk of heart attacks, strokes, or premature death within just three months after beginning treatment.

Co-author Professor Donna Ryan from the Pennington Biomedical Research Center emphasized that these results could reshape public health policies globally. She pointed out that in the U.S., the Medicare system already prescribes these treatments to patients with cardiovascular disease and sleep apnea.

“This analysis shows the treatment is effective early on. Why delay?” she questioned.

Dr. Louis J. Aronne, who oversees the Comprehensive Weight Control Center at Weil Cornell Medicine in New York, expressed anticipation for more innovations as he leads Munjaro’s initial head-to-head comparison trial.

“I think we’re entering a golden age of obesity treatment,” he remarked during discussions.

Dr. Sonya Babu-Narayan, clinical director and consultant cardiologist at the British Heart Foundation, reiterated the significance of these advancements in healthcare.

Professor John Deanfield from University College London described the current landscape as an “exciting new world,” noting that these drugs could play a crucial role in addressing not only obesity but also various diseases, highlighting an unprecedented volume of new drug development.

“There’s going to be a surge of trials,” he predicted, mentioning that around 150 drugs are in development.

One such drug, letutortide, has reportedly helped trial participants lose up to 24% of their body weight in less than a year. Its manufacturer, Lilly, plans to announce the results from the Phase 3 trial by year’s end.

Additionally, the NHS is set to begin prescribing Mounjaro next month to certain eligible patients. Dr. Claire Fuller, NHS Medical Director for Primary Care, noted that this rollout will allow access for those with the greatest clinical needs, with around 220,000 people expected to benefit over the next three years.

Experts in obesity are urging the government to expedite the inclusion of weight loss medications in its decade-long health strategy.

“If we’re serious about preventing obesity, we need to reconsider how quickly we make these drugs available,” stated Jason Halford, a professor at the European Association for Obesity Research.

Deanfield commented that these treatments should significantly contribute to the government’s prevention agenda, suggesting that GLP-1 drugs offer a chance to alleviate various aging-related ailments.

“I hope we won’t wait a decade to implement such crucial and transformative measures,” he added.

A spokesperson for the Ministry of Health and Social Care emphasized the seriousness of obesity and acknowledged that while medications can be transformative, they should complement, not replace, a balanced diet and regular exercise.

“As the government aims to shift the NHS from a reactive to a preventive model, we will explore ways to make these medications accessible to more individuals while ensuring they remain cost-effective for taxpayers,” the spokesperson concluded.